mdc-TJK (Olanzapine LAI)
Schizophrenia
Phase 3Active
Key Facts
About MedinCell
MedinCell is a clinical-stage biotech company with a commercial-stage product, specializing in long-acting injectable drug delivery via its proprietary BEPO® technology. The company has successfully partnered with major pharmaceutical firms like Teva, leading to the FDA-approved schizophrenia treatment UZEDY® and a late-stage pipeline including a promising olanzapine LAI. With a recent ~€48 million private placement and a growing revenue stream from its partnered product, MedinCell is positioned to expand its impact in psychiatry and other therapeutic areas while advancing its internal pipeline.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| DSP-2230 (ulotaront) | Sumitomo Pharma | Phase 3 |
| RBP-7000 (risperidone depot) | Indivior PLC | Approved |
| COBENFY® (xanomeline/trospium) | Zai Lab | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |